$12.23
0.10.82%
Últ. Act.: Oct 29, 4:17 AM
Pharming (PHAR) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Pharming (PHAR) publicó su última previsión de octubre 27, 2026 para fiscal year 2026. La compañía estimó ingresos en un rango de $380M - $390M para el período.
En comparación con la previsión anterior, Pharming mantenido redujo su previsión de ingresos desde un rango anterior de $380M - $390M.
Pharming ha emitido 16 actualizaciones de orientación entre el enero 8, 2024 y el octubre 27, 2026. During this period, the company raised its outlook 7 times and lowered it 2 times, providing investors with insight into management's evolving expectations.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.23 | $0.09 | $0.01 | $0.07 |
| Actual | $0.30 | $0.02 | $-0.07 | $0.07 |
| Surprise | +30.4% | -77.8% | -800.0% | 0.00% |
| Revenue | ||||
| Estimate | $117.6M | $101.2M | $92.4M | $95.7M |
| Actual | $117.6M | $90.2M | $72.4M | $106.5M |
| Surprise | 0.00% | -10.8% | -21.6% | +11.2% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.06 | $-0.03 | $0.06 | $0.27 |
| Revenue | ||||
| Consensus | $107.5M | $77.0M | — | — |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q3 | Oct 27, 2026 | $0.30 | $0.23 | 30.4 % |
| Q2 | Jul 30, 2026 | $0.02 | $0.09 | -77.8 % |
| Q1 | May 7, 2026 | $-0.07 | $0.01 | -800.0 % |
| Q4 | Mar 12, 2026 | $0.07 | $0.07 | 0.00 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q3 | Oct 27, 2026 | $117.60M | $117.60M | 0.00 % |
| Q2 | Jul 30, 2026 | $90.20M | $101.15M | -10.8 % |
| Q1 | May 7, 2026 | $72.40M | $92.40M | -21.6 % |
| Q4 | Mar 12, 2026 | $106.50M | $95.75M | 11.2 % |